H2020Индивидуална стипендия2017–2019

ColoFILM · Multifunctional polymeric film-based drug delivery system for oral anti-TNF-alpha-based inflammatory bowel disease therapy

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2017-05-01 → 2019-04-30
Финансиране от ЕС: 172 800 €
Участници: 1
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Специални полимерни филми с наночастици транспортират лекарства за възпалителни заболявания на червата директно до мястото на възпалението. Това помага за намаляване на страничните ефекти от системното приложение на антителата и подобрява качеството на живот на пациентите.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Multifunctional polymeric film-based drug delivery system for oral anti-TNF-alpha-based inflammatory bowel disease therapy

Inflammatory bowel disease (IBD) is an umbrella term to define relapsing chronic inflammation of the gastrointestinal (GI) tract. Ulcerative colitis and Crohn’s disease are its two variants. IBD is one of the most prevalent GI diseases, especially in Western countries with ca. 2.5–3.0 million cases in Europe and an estimated direct annual health-care cost of €4.6–5.6 billion. Conventional IBD therapies include drugs such as aminosalicylates, corticosteroids, thiopurines, which mainly provide symptomatic relief. Currently, antibodies against TNF-α (anti-TNF-α) are considered as second line of treatment. However, the use of anti-TNF-α is limited to systemic administration, which in turn has serious adverse effects such as opportunistic infections, infusion reactions, and autoimmune diseases. IBD can. In addition to major adverse effect, IBD has a colossal socio-economic impact by greatly deterring patient’s quality of life by impeding their daily (personal and professional) lives, instilling social stigma and afflicting substantial healthcare costs. Therefore, the aim of the project has been to develop an advanced drug delivery system that could target and localize the anti-TNF-α antibody at the site of action with minimal exposure to systemic circulation and other healthy tissues, which would overcome the critical limitations of the current therapeutic approach to provide safer and efficacious anti-TNF-α therapy for IBD patients. During the project period, we successfully developed nanoparticles-in-film formulation, which encapsulated anti-TNF-α antibody. We demonstrated that after oral administration of antibody-loaded nanoparticles, the inflammatory markers were greatly reduced in murine colitis model.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The prevalence and occurrence of inflammatory bowel diseases have experienced steep increase in Western countries, as well as in populations considered ‘low risks’ before. Nevertheless, currently available therapies, including anti-tumor necrosis factor-α (TNF-α) therapy, have numerous limitations and are often associated with severe adverse effects. Therefore, the research project aims at safer and effective inflammatory bowel disease therapy by proposing development of a novel multifunctional polymeric film based platforms for oral delivery of anti-TNF-α. The drug delivery system comprises of a nanoformulation encapsulating anti-TNF-α which are then entrapped into a mucoadhesive polymeric film. These mucoadhesive polymeric films are composed of second generation highly efficient mucoadhesive S-protected thiolated polymer, which are then loaded inside pH responsive capsules for site-specific delivery. The proposed system would provide enhanced therapeutic outcome by minimizing side effect via reduction of the frequency of dosing and targeted delivery of anti-TNF-α at the site of action, which would be achieved by preventing the degradation of the encapsulated biologics, prolonging the gastrointestinal retention time of the drug delivery system, increasing drug accumulation at target site and minimizing the systemic absorption. Furthermore, additional unique benefits of the proposed systems such as the biocompatibility, biodegradability, sustained drug release at targeted site, mucus penetration of the nanoformulation, and use of accessible and patient friendly oral route, can widen its biomedical applicability and explore its use in clinics and pharmaceutical industries.

Оригинален текст от CORDIS (на английски).

Участници

UNIVERSITE CATHOLIQUE DE LOUVAIN · LOUVAIN LA NEUVEКоординаторБелгия